Aadi Bioscience, INC Form 4 insider transactions

Whitehawk Therapeutics, Inc. director Caley Castelein was granted 40,006 stock options with an exercise price of $2.04, vesting over one year or prior to the next annual meeting.

Anupam Dalal, a Director and 10% owner of Whitehawk Therapeutics, Inc., was granted 40,006 stock options with an exercise price of $2.04, vesting over one year or prior to the next annual meeting.

A recent SEC Form 4 filing reveals that Behzad Aghazadeh, a director and 10% owner of Whitehawk Therapeutics, Inc., was granted 40,006 stock options with an exercise price of $2.04, vesting over one year or until the next annual meeting.

Bryan Ball, Chief Technical Operations Officer and SVP of Manufacturing Operations at Whitehawk Therapeutics, acquired stock options and restricted stock units on April 1, 2025.

Scott M. Giacobello, CFO of Whitehawk Therapeutics, reports the acquisition of stock options and restricted stock units (RSUs) as part of his compensation.

Whitehawk Therapeutics CEO David James Lennon was granted stock options and restricted stock units on April 1, 2025, according to a Form 4 filing.

Director Anupam Dalal reports acquiring 1,561,000 shares of Aadi Bioscience, Inc. common stock at $2.4 per share on March 4, 2025.

Director Caley Castelein reports acquiring 1,666,000 shares of Aadi Bioscience, Inc. common stock on March 4, 2025, at a price of $2.4 per share.

Director Zhao Baiteng reports acquisition of 1,250,000 shares of Aadi Bioscience common stock at $2.4 per share on March 4, 2025.

David Dornan, Chief Scientific Officer of Aadi Bioscience, Inc., reports the acquisition of stock options.

Bryan Ball, Chief Technical Operations Officer and SVP, Manufacturing Operations at Aadi Bioscience, reports acquisition and disposal of company stock and stock units.

Avoro Capital Advisors, Avoro Ventures, and Behzad Aghazadeh acquired pre-funded warrants for Aadi Bioscience common stock in a private placement, subject to a 19.99% ownership blocker.

Scott Giacobello, CFO of Aadi Bioscience, reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

CEO David James Lennon of Aadi Bioscience, Inc. reports the acquisition and disposal of company stock and restricted stock units.

Aadi Bioscience director, Zhao Baiteng, acquired 61,192 stock options on December 19, 2024, which vest over three years.

Aadi Bioscience CEO David Lennon exercised stock options and sold a portion of the acquired shares to cover tax obligations.

Neil Desai, Executive Chairman of Aadi Bioscience, Inc., sold 40,000 shares of common stock on September 3, 2024, at an average price of $1.7079.

Neil Desai, Executive Chairman of Aadi Bioscience, sold shares of common stock between August 1 and August 5, 2024, according to a Form 4 filing with the SEC.

Neil Desai, Executive Chairman of Aadi Bioscience, sold shares of the company's common stock on July 1st and 2nd, 2024, according to a Form 4 filing with the SEC.

Behzad Aghazadeh, along with Avoro Capital Advisors and Avoro Ventures, reports the acquisition of stock options in Aadi Bioscience, Inc.

Director Richard E. Maroun acquired stock options in Aadi Bioscience, Inc. on June 12, 2024.

Director Mohammad Hirmand acquired stock options for 45,832 shares of Aadi Bioscience, Inc. on June 12, 2024.

Director Emma Reeve reports the acquisition of stock options in Aadi Bioscience, Inc.

Director Caley Castelein of Aadi Bioscience, Inc. acquired stock options for 45,832 shares on June 12, 2024.

Anupam Dalal, a director of Aadi Bioscience, acquired stock options for 45,832 shares on June 12, 2024.

Director Karin M. Hehenberger acquired stock options in Aadi Bioscience, Inc. on June 12, 2024.

Neil Desai, Executive Chairman of Aadi Bioscience, sold shares of the company's common stock on June 3rd and 4th, 2024, according to a Form 4 filing with the SEC.

Neil Desai, Executive Chairman of Aadi Bioscience, Inc., sold 40,000 shares of common stock at an average price of $1.9296 on May 1, 2024, according to a Form 4 filing with the SEC.

Neil Desai, Executive Chairman of Aadi Bioscience, sold shares of common stock on April 1st and 2nd, 2024, according to a Form 4 filing with the SEC.

Neil Desai, Executive Chairman of Aadi Bioscience, sold shares of the company's common stock on March 1 and March 4, 2024, according to a Form 4 filing with the SEC.